IP Library Granted Patent US 10,724,087
Granted Patent B2
US 10,724,087 · App. 15/674,653 · Granted Jul 28, 2020

Enzyme method

Inventors: Ruth Moysey (Oxford, GB); Andrew John Heron (Oxford, GB)
Assignee: Oxford Nanopore Technologies Ltd.
C12Q1/6869C12Q2521/513C12Q2565/631
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,724,087
App. No.
15/674,653
Granted
Jul 28, 2020
Kind
B2
Abstract

The invention relates to a new method of characterizing a target polynucleotide. The method uses a pore and a Hel308 helicase or amolecular motor which is capable of binding to the target polynucleotide at an internal nucleotide. The helicase or molecular motor controls the movement of the target polynucleotide through the pore.

Claims (16)

1. A method of characterising a target polynucleotide, comprising:

(a) contacting the target polynucleotide with a transmembrane pore, wherein a first helicase is bound to the target polynucleotide such that the first helicase controls the movement of the target polynucleotide through the pore;

(b) further contacting the target polynucleotide with a second helicase as the first helicase controls the movement of the target polynucleotide through the transmembrane pore, wherein the second helicase binds to an internal polynucleotide of the target polynucleotide at a location on the polynucleotide different than where the first helicase is bound without concurrent binding to a terminal nucleotide of the target polynucleotide, and wherein the second helicase controls movement of the target polynucleotide through the pore after the first helicase disengages from the target polynucleotide; and

(c) measuring one or more characteristics of the target polynucleotide during one or more interactions as the target polynucleotide moves through the transmembrane pore, wherein the one or more interactions are measured along a length of the target polynucleotide that comprises at least 500 nucleotides and exceeds processivity of the first helicase, thereby characterising the target polynucleotide.

2. The method according to claim 1 , wherein the second helicase is a Hel308 helicase, Hel308 Tga, Hel308 Mhu or Hel308 Csy.

3. The method according to claim 2 , wherein the Hel308 helicase comprises the amino acid motif Q-X1-X2-G-R-A-G-R (SEQ ID NO: 8), wherein X1 is C, M or L and X2 is any amino acid residue, preferably wherein X2 is A, F, M, C, V, L, I, S, T or P.

4. The method according to claim 2 , wherein the Hel308 helicase is one of the helicases shown in Table 4 or 5 or wherein the Hel308 helicase comprises the sequence shown in any one of SEQ ID NOs: 10, 13, 16, 19, 22, 25, 28, 29, 32, 33, 34, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55; and 58.

5. The method according to claim 1 , wherein the one or more characteristics are selected from (i) the length of the target polynucleotide, (ii) the identity of the target polynucleotide, (iii) the sequence of the target polynucleotide, (iv) the secondary structure of the target polynucleotide, and (v) whether or not the target polynucleotide is modified by methylation, by oxidation, by damage, with one or more proteins or with one or more labels, tags or spacers.

6. The method according to claim 1 , wherein the one or more characteristics of the target polynucleotide are measured by electrical measurement and/or optical measurement.

7. The method according to claim 6 , wherein the electrical measurement is a current measurement, an impedance measurement, a tunnelling measurement, or a field effect transistor (FET) measurement.

8. The method according to claim 1 , wherein the method further comprises the step of applying a voltage across the pore to form a complex between the pore and the first helicase and wherein at least a portion of the polynucleotide is double stranded.

9. The method according to claim 1 , wherein the transmembrane pore is a protein pore or a solid state pore.

10. The method according to claim 9 , wherein the pore is a transmembrane protein pore selected from a hemolysin, leukocidin, Mycobacterium smegmatis porin A (MspA), outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A, Neisseria autotransporter lipoprotein (NalP) and WZA.

11. The method according to claim 9 , wherein the transmembrane protein is (a) formed of eight identical subunits as shown in SEQ ID NO: 2, or (b) α-hemolysin formed of seven identical subunits as shown in SEQ ID NO: 4.

12. The method according to claim 1 , wherein method is carried out using a salt concentration of at least 0.3 M or at least 1.0 M and the salt is optionally KCl.

13. The method according to claim 1 , wherein the one or more interactions are measured along a length of the target polynucleotide that comprises at least 1000 nucleotides.

Assignments (2)
CHANGE OF NAME Recorded Aug 16, 2023
From: OXFORD NANOPORE TECHNOLOGIES LIMITED
To: OXFORD NANOPORE TECHNOLOGIES PLC
Reel/Frame 064673/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: MOYSEY, RUTH; HERON, ANDREW JOHN
To: OXFORD NANOPORE TECHNOLOGIES LTD.
Reel/Frame 044592/0818 →
Continuity (5)
Continuation 14351038
Provisional Application 61599244 · Feb 15, 2012
Provisional Application 61549998 · Oct 21, 2011
Related Publication 20180030530A1 · Feb 1, 2018
Related Publication 20180216175A9 · Aug 2, 2018
Cited By (4)
US 12,215,384 US 12,252,717 US 12,258,591 US 12,503,729